Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Employees

528

Sector

Biotechnology & Medical Research

Calendar

04/03 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
21/26/21	499.53 $	-1.07%	83,082
20/26/20	504.95 $	+0.65%	2,22,773
16/26/16	501.68 $	+1.17%	2,76,248
15/26/15	495.88 $	-1.85%	2,17,630
14/26/14	505.23 $	+2.29%	3,46,659

Delayed Quote Nasdaq, January 21, 2026 at 11:57 pm IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

504.95USD

Average target price

635.21USD

Spread / Average Target

+25.80%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 12:12:32 22/01/2026 am IST			5-day change	1st Jan Change
498.96 ^USD	-1.19%		-1.13%	-14.22%

04:54am	Madrigal Pharmaceuticals Insider Sold Shares Worth $344,173, According to a Recent SEC Filing	MT
21/01	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,098,343, According to a Recent SEC Filing	MT

Capitalization	1.15TCr 980.53Cr 910.2Cr 853.64Cr 1.58TCr 1,05000Cr 1.7TCr 10TCr 4.13TCr 50TCr 4.3TCr 4.21TCr 1,81300Cr	P/E ratio 2025 *	-46.3x	P/E ratio 2026 *	1,181x
Enterprise value	1.09TCr 933.56Cr 866.6Cr 812.75Cr 1.51TCr 1,00000Cr 1.61TCr 9.95TCr 3.94TCr 47TCr 4.09TCr 4.01TCr 1,72700Cr	EV / Sales 2025 *	11.5x	EV / Sales 2026 *	7.44x
Free-Float	91.44%	Yield 2025 *	-	Yield 2026 *	-

04:54am	Madrigal Pharmaceuticals Insider Sold Shares Worth $344,173, According to a Recent SEC Filing	MT
21/01	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,098,343, According to a Recent SEC Filing	MT
14/01	Madrigal Pharmaceuticals Insider Sold Shares Worth $9,617,312, According to a Recent SEC Filing	MT
13/01	Madrigal Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM
09/01	Madrigal Pharmaceuticals, Inc. Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor	CI
09/01	Madrigal expands its mash pipeline with exclusive global license agreement for ervogastat	RE
09/01	Madrigal Pharmaceuticals Granted Worldwide Exclusivity for Pfizer Liver Disease Drug	MT
19/12	Altimmune's liver disease drug shows benefits in study, but investors remain unimpressed	RE
12/12	Madrigal Pharmaceuticals, Inc. Appoints Rita Thakkar as Senior Vice President and Chief Accounting Officer, Effective January 12, 2026	CI
11/12	B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating	MT
05/12	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing	MT
04/12	Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash	CI
04/12	Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals	RE

11/12	B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating	MT
20/11	Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating	MT
19/11	Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating	MT
06/11	Madrigal Pharmaceuticals Shares Rise After Cantor Fitzgerald Upgrade	MT
05/11	Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals to Overweight From Neutral	MT

Madrigal Pharmaceuticals, Inc. Share Price

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Valuation: Madrigal Pharmaceuticals, Inc.

Chart: Madrigal Pharmaceuticals, Inc.

Latest news: Madrigal Pharmaceuticals, Inc.

Last Transcript: Madrigal Pharmaceuticals, Inc.

Analysts' recommendations: Madrigal Pharmaceuticals, Inc.

Press Releases: Madrigal Pharmaceuticals, Inc.

News in other languages: Madrigal Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Madrigal Pharmaceuticals, Inc.

ETFs: Madrigal Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

13/01	Madrigal Pharmaceuticals : MDGL JPM 2026 Presentation	PU
09/01	Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor	AQ
19/12	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
16/12	Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
12/12	Madrigal Pharmaceuticals : Corporate Governance Guidelines (83982c)	PU

30/25/30	Madrigal Pharmaceuticals : va débourser jusqu'à 2 milliards de dollars pour une molécule
30/25/30	USA-Les valeurs à suivre à Wall Street (actualisé)
20/25/20	USA-Les valeurs à suivre à Wall Street (actualisé)
19/24/19	EE.UU. - Valores a seguir en Wall Street (actualizado)
19/24/19	Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -

1 day	-1.11%
1 week	-1.13%
Current month	-14.22%
1 month	-17.14%
3 months	+16.17%
6 months	+50.94%
Current year	-14.22%

1 week	483.55	511.94
1 month	483.55	615
Current year	483.55	598.79
1 year	265	615
3 years	119.76	615
5 years	52.33	615
10 years	6.6	615

Manager	Title	Age	Since
William Sibold CEO	Chief Executive Officer	59	08/09/2023
Edward Chiang CTO	Chief Tech/Sci/R&D Officer	-	01/09/2011
Mardi Dier DFI	Director of Finance/CFO	62	11/03/2024

Director	Title	Age	Since
Paul Friedman CHM	Chairman	83	22/07/2016
Rebecca Taub BRD	Director/Board Member	74	01/07/2016
Ken Bate BRD	Director/Board Member	75	22/07/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MADRIGAL PHARMACEUTICALS, INC.	-1.19%	-1.13%	+62.67%	+63.81%	1.15TCr
ARGENX SE	+1.49%	+0.75%	+11.11%	+91.74%	4.92TCr
WUXI APPTEC CO., LTD.	-0.91%	-5.78%	+75.89%	+1.08%	4.25TCr
INSMED INCORPORATED	-2.81%	-2.64%	+107.35%	+646.79%	3.49TCr
BIONTECH SE	+8.24%	+4.37%	-2.87%	-20.76%	2.65TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.50%	-3.47%	+105.35%	-46.18%	1.97TCr
GENMAB A/S	+4.50%	-7.24%	+35.98%	-23.26%	1.93TCr
AKESO, INC.	-3.06%	-5.47%	+90.64%	+138.49%	1.39TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.94%	-10.69%	+156.05%	-	1.32TCr
SUMMIT THERAPEUTICS INC.	+1.03%	-8.27%	-26.74%	+263.00%	1.24TCr
Average	+0.77%	-3.68%	+61.54%	+123.86%	2.43TCr
Weighted average by Cap.	+0.93%	-3.22%	+57.26%	+135.41%

	2025 *	2026 *
Net sales	95Cr 81Cr 75Cr 71Cr 130.91Cr 8.68TCr 140.18Cr 863.47Cr 341.69Cr 4.1TCr 355.49Cr 348.22Cr 15TCr	145.84Cr 124.69Cr 115.75Cr 108.56Cr 201.4Cr 13TCr 215.65Cr 1.33TCr 525.68Cr 6.31TCr 546.9Cr 535.71Cr 23TCr
Net income	-23Cr -20Cr -18Cr -17Cr -32Cr -2.12TCr -34Cr -211.11Cr -84Cr -1TCr -87Cr -85Cr -3.66TCr	73.88L 63.17L 58.64L 54.99L 1.02Cr 68Cr 1.09Cr 6.73Cr 2.66Cr 32Cr 2.77Cr 2.71Cr 116.83Cr
Net Debt	-55Cr -47Cr -44Cr -41Cr -76Cr -5.03TCr -81Cr -500.39Cr -198.01Cr -2.38TCr -206.01Cr -201.79Cr -8.69TCr	-61Cr -52Cr -49Cr -46Cr -85Cr -5.62TCr -91Cr -558.78Cr -221.12Cr -2.66TCr -230.05Cr -225.34Cr -9.7TCr